News
Click on one of our recent press releases to read more.
June 14, 2023 – T-CURE BIOSCIENCE ANNOUNCES DR. GANG ZENG GUEST SPEAKER AT TWO UPCOMING IMMUNOTHERAPY SUMMITS
Sherman Oaks, CA – June 14, 2023 T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the management will present virtually at the following upcoming healthcare conferences:11th Annual Immuno-oncology Summit, [...]
October 6, 2022 – NCI AND RUTGERS UNIVERSITY OPEN PHASE 1 CLINICAL TRIALS OF T CELL RECEPTOR THERAPY TARGETING KK-LC-1 FOR MULTIPLE SOLID TUMORS
LOS ANGELES, CA – October 6, 2022 - T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are [...]
October 5, 2021 – T-CURE BIOSCIENCE, INC. AND ATLAS ANTIBODIES AB ENTER A COLLABORATION AGREEMENT FOR THE DEVELOPMENT, MANUFACTURE, AND SUPPLY OF CT83 (KK-LC-1) MONOCLONAL ANTIBODIES
LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for [...]
September 15, 2021 – T-CURE BIOSCIENCE ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATOR – INITIATED CLINICAL TRIAL FOR KK-LC-1 TCR-T AGAINST MULTIPLE SOLID TUMORS
LOS ANGELES, CA, September 15, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor therapy (TCR-T) products for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational [...]
September 10, 2021 – T-CURE BIOSCIENCE ANNOUNCED PRESENTATIONS AT THREE UPCOMING HEALTHCARE CONFERENCES
Sherman Oaks, CA – September 10, 2021 - T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the management will present virtually at the following upcoming healthcare conferences:5th [...]
April 16, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:
Sherman Oaks, CA – April 16, 2021 - T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and [...]
March 17, 2021 – T-Cure Bioscience Enters Into Agreement With Rutgers to Conduct Clinical Research of Novel T Cell Receptor Therapy for Treatment of Variety of Cancers
Sherman Oaks, CA – March 17, 2021 - T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with [...]
January 20, 2021 – T-Cure Bioscience and Immunotech Biopharm Ltd. Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
Immunotech Biopharm Ltd will have rights to develop and commercialize 800TCR, a HERV-E targeting T cell receptor (TCR) therapy for the treatment of kidney cancer, in China T- Cure Bioscience to receive an upfront payment and future development milestones and royalties Sherman Oaks, [...]
August 04, 2020 – T-Cure Bioscience Announces Expansion of Collaboration With the National Institutes of Health for T Cell Receptor (TCR) Therapy Targeting HERV-E for the Treatment of Kidney Cancer
Sherman Oaks, CA – August 04, 2020 – (BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has extended its ongoing research collaboration [...]
April 20, 2020 – T-CURE ANNOUNCES APPOINTMENT OF SEASONED INDUSTRY EXECUTIVE JAMES G. MCARTHUR, PH.D. TO BOARD OF DIRECTORS
Los Angeles, CA – April 20, 2020 – T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced the appointment of seasoned biopharmaceutical industry executive James G. McArthur, [...]
April 08, 2020 – T-CURE BIOSCIENCE SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH NCI
LOS ANGELES, CA – April 8, 2020 – T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into an exclusive, worldwide license [...]